- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02954341
CardioMEMS HF System OUS Post Market Study
February 16, 2024 updated by: Abbott Medical Devices
The purpose of this Post Market Study (PMS) is to evaluate the use of the CardioMEMS HF System in patients with Class III Heart Failure in a commercial setting.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Queensland
-
Chermside, Queensland, Australia, 4032
- The Prince Charles Hospital
-
-
-
-
-
Liège, Belgium
- CHR Citadelle
-
-
-
-
-
Copenhagen, Denmark
- Rigshospitalet
-
-
-
-
-
Lille, France
- CHRU de Lille
-
-
-
-
-
London, United Kingdom
- Royal Bromptom Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Adults with New York Heart Association (NYHA) Class III Heart Failure (HF) who have experienced a heart failure hospitalization within the past 12 months.
Description
Inclusion Criteria:
- Written informed consent obtained from subject
- ≥ 18 years of age
- Diagnosis of NYHA Class III Heart Failure
- At least 1 HF hospitalization within 12 months of Baseline visit
- Subjects with reduced LVEF heart failure should be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB.
- Subjects with a BMI ≤ 35. Subjects with BMI >35 will require their chest circumference to be measured at the axillary level, if > 65 inches the patient will not be eligible for the study.
- Subjects with pulmonary artery branch diameter ≥ 7mm - (implant target artery - assessed during the RHC)
- Subjects willing and able to comply with the follow-up requirements of the study
Exclusion Criteria:
- Subjects with an active infection
- Subjects with history of recurrent (> 1) pulmonary embolism or deep vein thrombosis
- Subjects who, in the Investigator's opinion, are unable to tolerate a right heart catheterization
- Subjects who have had a major cardiovascular event (e.g., myocardial infarction, open heart surgery, stroke, etc.) within 2 months of Baseline Visit
- Subjects with Cardiac Resynchronization Device (CRT) implanted < 3 months prior to enrollment
- Subjects with a Glomerular Filtration Rate (GFR) < 25 ml/min (obtained within 2 weeks of the baseline visit) who are non-responsive to diuretic therapy or who are on chronic renal dialysis
- Subjects with congenital heart disease or mechanical right heart valve(s)
- Subjects likely to undergo heart transplantation or VAD within 6 months of baseline visit
- Subjects with known coagulation disorders
- Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel (not applicable for subjects taking anti-coagulation therapy or other approved anti-platelets therapy).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Freedom from device/system related complications
Time Frame: Two year
|
Two year
|
Freedom from pressure sensor failure.
Time Frame: Two year
|
Two year
|
Annualized HF hospitalization rate at 1 year compared to the HF hospitalization rate in the year prior to enrollment.
Time Frame: One year
|
One year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Martin R Cowie, MD, Royal Brompton & Harefield NHS Foundation Trust
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cowie MR, Flett A, Cowburn P, Foley P, Chandrasekaran B, Loke I, Critoph C, Gardner RS, Guha K, Betts TR, Carr-White G, Zaidi A, Lim HS, Hayward C, Patwala A, Rogers D, Pettit S, Gazzola C, Henderson J, Adamson PB. Real-world evidence in a national health service: results of the UK CardioMEMS HF System Post-Market Study. ESC Heart Fail. 2022 Feb;9(1):48-56. doi: 10.1002/ehf2.13748. Epub 2021 Dec 9.
- Cowie MR, de Groote P, McKenzie S, Brett ME, Adamson PB; CardioMEMS Post-Market Study Investigators. Rationale and design of the CardioMEMS Post-Market Multinational Clinical Study: COAST. ESC Heart Fail. 2020 Jun;7(3):865-872. doi: 10.1002/ehf2.12646. Epub 2020 Feb 7.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
December 8, 2023
Study Completion (Actual)
December 8, 2023
Study Registration Dates
First Submitted
October 21, 2016
First Submitted That Met QC Criteria
November 1, 2016
First Posted (Estimated)
November 3, 2016
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 16, 2024
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SJM-CIP-10147
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on CardioMEMS HF System
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Abbott Medical DevicesCompletedHeart Failure | Congestive Heart Failure | Left-Sided Heart FailureUnited States
-
Abbott Medical DevicesCompleted
-
Sheffield Teaching Hospitals NHS Foundation TrustRecruiting
-
Abbott Medical DevicesEnrolling by invitationHeart Failure NYHA Class II | Heart Failure NYHA Class IIIUnited States
-
Universitaire Ziekenhuizen KU LeuvenAbbottRecruitingPulmonary Hypertension | Heart Failure With Preserved Ejection FractionBelgium
-
CardioMEMSCompletedNYHA Class III Heart FailureUnited States
-
Abbott Medical DevicesCompleted
-
Finn GustafssonNovo Nordisk A/S; AbbottRecruitingHeart Failure With Reduced Ejection Fraction | Advanced Heart FailureDenmark
-
Centre Hospitalier Universitaire de NīmesCHU Arnaud de Villeneuve MONTPELLIERRecruiting